Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 7/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996471 | 0.86 | MAPK14 (0.40) | TYK2FGFR4CSNK2A2MAPK14 | |
| SCHEMBL3310314 | 0.85 | KCNH2 (0.44) | TYK2FGFR4CSNK2A2MAPK14 | |
| SCHEMBL12012940 | 0.85 | MAPK14 (0.41) | TYK2FGFR4CSNK2A2MAPK14 | |
| SCHEMBL3313469 | 0.85 | CSNK2A2 (0.42) | TYK2FGFR4CSNK2A2DYRK1A | |
| SCHEMBL3310725 | 0.84 | TYK2 (0.52) | TYK2PDE4DCSNK2A2 | |
| SCHEMBL13644218 | 0.81 | CSNK2A2 (0.41) | TYK2FGFR4CSNK2A2DYRK1A | |
| SCHEMBL3313250 | 0.77 | CSNK2A2 (0.39) | FGFR4CSNK2A2DYRK1AFYN | |
| SCHEMBL3313136 | 0.76 | TYK2 (0.49) | TYK2PDE4DCSNK2A2 | |
| SCHEMBL3311742 | 0.76 | CSNK2A1 (0.46) | TYK2PDE4DCSNK2A2DYRK1AMAPK14 | |
| SCHEMBL13641722 | 0.75 | TYK2 (0.39) | TYK2PDE4DCSNK2A2MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2350081-B1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885FGFR4 1079/4885PDE4D 1445/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885FGFR4 1079/4885PDE4D 1445/4885 |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885FGFR4 1079/4885PDE4D 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.